NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.
The company's loss of the three-month period ended June 30 was $2 million, the same as the year before. Research and development spending held steady at $1.2 million, while general and administrative costs edged up $100,000 to $1 million.
At the end of the quarter, RXi had cash and cash equivalents of roughly $11.9 million.